Press Releases

Creative Bioarray Launches Cell Immortalization Services to Extend Replicative Capacity of Target Cells and Accelerate Biomedical Research

DDA Platform Releases In Vitro Permeability Assay to Evaluate Drug Permeability and Predict Drug Absorption

Verana Health Launches Population Health Data Engine to Accelerate Clinical Research, Advance Medical Care, and Improve Patient Outcomes

Verana Health Launches Population Health Data Engine to Accelerate Clinical Research, Advance Medical Care, and Improve Patient Outcomes

Creative Biogene Eatablished An Excellent Platform to Provide High Quality Virus-Like Particles

IntegrateRNA Launched Comprehensive LncRNA Pull-down Services: Supporting The Validation of LncRNA Biology

Calyx RIM Selected by Top 10 Global Pharmaceutical Company for Five-Year Agreement

Regulatory publishing solution selected based on reliability and innovation

BioIVT to Showcase Drug Discovery Research Advances Using Novel Hepatotoxicity Models

Researchers will discuss how they employed HEPATOPAC® and HEPATOMUNE® cultures in their disease modeling, lead selection, and ADME evaluation programs.

Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category

The MALDI-Imaging Lipidomics Service Is Now Available Through Lipidomics Platform

Profacgen Enables Custom Bioinformatics Software Development for Researchers Worldwide

CD ComputaBio Announces 3D-QSAR Service for Drug Design and Screening

CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company has recently launched 3D-QSAR services for scientists to accelerate the drug development process.

CluePoints Shortlisted for Multiple Awards in Recognition of Pioneering Risk-Based Quality Management Solution

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, has announced it has been shortlisted for three international awards. CluePoints, BioNTech and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty) has been selected as a finalist for the Clinical Advance of the Year - COVID-19 Pandemic Special Recognition Award at the Scrip Awards. The company is also in the running for two Citeline Awards: ´Best Sponsor-facing Technology Initiative´ for their business intelligence platform, BEYOND. As well as ´Excellence in Innovation in Response to COVID-19 - Clinical Trial Activities´, for its work with Pfizer / BioNTech.

CD Formulation Offers Multiple Methods for Microbial Limit Test

Cardinal Health Awarded FDA Funding to Assess Real World Evidence Results Against Clinical Trials

Cardinal Health will explore how to better standardize real world evidence for use in regulatory decisions

Rho’s Chief Medical Officer Jack Modell Presenting During 12th Annual CNS Summit

Rho, a full-service contract research organization (CRO), is showcasing its clinical development expertise during the 12th Annual CNS Summit, taking place at the Encore Boston Harbor Hotel from November 7-10, 2021. Rho’s Chief Medical Officer, Dr. Jack Modell, along with Dr. John Greist and Dr. Thomas Laughren, will present during a Spotlight Session at the Summit. The 50-minute breakout session, titled, “The Seven Essentials of Clinical Development: How to Avoid Shooting Yourself in the Foot” will showcase the speakers’ combined experience in clinical medicine, academic research, regulatory affairs, and development of drugs and medical applications of information technology.

Two Top 5 Global Pharmaceutical Companies Affirm Their Trust in Calyx RIM, Execute Long-Term Contract Extensions

Ability to meet evolving requirements, including IDMP, ensures regulatory compliance for leading companies

Rho to Coordinate NIAID COVID‐19 Vaccine Study in Autoimmune Disease Non‐Responders

Rho , a full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it will be the Statistical and Clinical Coordinating Center for the COVID-19 Vaccine in Autoimmune Disease Non-Responders study. This clinical trial will assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune diseases who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune diseases improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline

The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.

Emmes launches Orphan Reach™: Emmes’ Rare Disease Center

The new global Rare Disease center of Emmes expects accelerating growth from US and European biotechs

TARA Biosystems Partners with Scipher Medicine®

TARA Biosystems, a biotechnology company harnessing human biology and data to transform cardiac drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company matching patients with the most effective therapy. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.